These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 7188585)
41. Different antihypertensive effect of beta-blocking drugs in low and normal-high renin hypertension. Kralberg BE; Tolagen K Am J Med; 1976 May; 60(6):891-6. PubMed ID: 14504 [TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetic properties and antihypertensive efficacy of once-daily diltiazem. Kelly JG; Devane JG; Geoghegan B J Cardiovasc Pharmacol; 1991 Jun; 17(6):957-63. PubMed ID: 1714021 [TBL] [Abstract][Full Text] [Related]
43. Long term treatment of moderate hypertension with penbutolol (Hoe 893d). I. Effects on blood pressure, pulse rate, catecholamines in blood and urine, plasma renin activity and urinary aldosterone under basal conditions and following exercise. Hansson BG; Hökfelt B Eur J Clin Pharmacol; 1975 Oct; 9(1):9-19. PubMed ID: 9298 [TBL] [Abstract][Full Text] [Related]
44. [Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK954, in patients with essential hypertension]. Hagino T; Abe K; Tsunoda K; Yoshinaga K Nihon Jinzo Gakkai Shi; 1992 Feb; 34(2):133-40. PubMed ID: 1588765 [TBL] [Abstract][Full Text] [Related]
45. 24-hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: magnitude and duration of antihypertensive effects. Ramipril Multicenter Study Group. McCarron D Clin Cardiol; 1991 Sep; 14(9):737-42. PubMed ID: 1835914 [TBL] [Abstract][Full Text] [Related]
46. Effects of doxazosin on blood pressure, renin-angiotensin-aldosterone and urinary kallikrein. Oliveros-Palacios MC; Godoy-Godoy N; Colina-Chourio JA Am J Cardiol; 1991 Jan; 67(2):157-61. PubMed ID: 1824806 [TBL] [Abstract][Full Text] [Related]
47. [Antihypertensive action of various talinolol dosages after four week's treatment in comparison with placebo]. Weigmann I; Terhaag B; Wierich W; Herrmann WM Arzneimittelforschung; 1998 Mar; 48(3):240-4. PubMed ID: 9553680 [TBL] [Abstract][Full Text] [Related]
48. Clinical experience with a once-daily, extended-release formulation of diltiazem in the treatment of hypertension. Graney WF Am J Med; 1992 Aug; 93(2A):56S-64S. PubMed ID: 1519637 [TBL] [Abstract][Full Text] [Related]
49. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242 [TBL] [Abstract][Full Text] [Related]
50. Evaluation of once daily endralazine in hypertension. Wu R; Spence JD; Carruthers SG Eur J Clin Pharmacol; 1986; 30(5):553-7. PubMed ID: 3758143 [TBL] [Abstract][Full Text] [Related]
52. Effects of the calcium antagonist felodipine on the sympathetic and renin-angiotensin-aldosterone systems in essential hypertension. Katzman PL; Hulthén UL; Hökfelt B Acta Med Scand; 1988; 223(2):125-31. PubMed ID: 3279724 [TBL] [Abstract][Full Text] [Related]
53. Cadralazine (ISF 2469): dose-related antihypertensive activity after single oral administration to patients. Catalano M; Parini J; Libretti A Eur J Clin Pharmacol; 1983; 24(2):157-61. PubMed ID: 6840161 [TBL] [Abstract][Full Text] [Related]
55. Clinical evaluation of endralazine (BO22708), a new vasodilator, in essential hypertension. Elliott HL; McLean K; Sumner DJ; Donnelly RJ; Reid JL Clin Exp Hypertens A; 1982; 4(8):1409-18. PubMed ID: 6749347 [TBL] [Abstract][Full Text] [Related]
56. Comparison of once daily endralazine with placebo in the treatment of hypertension uncontrolled by a beta-blocker and diuretic. McGourty JC; Silas JH; Pidgeon J Eur J Clin Pharmacol; 1985; 29(4):401-3. PubMed ID: 2868900 [TBL] [Abstract][Full Text] [Related]
57. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension. Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023 [TBL] [Abstract][Full Text] [Related]
58. A comparative study of endralazine and captopril in essential hypertension: effect on renin levels, pulmonary function studies and lipid profile. Hauger-Klevene JH; Reader C; Mayer E; Sanchez MR Int J Clin Pharmacol Res; 1986; 6(4):275-81. PubMed ID: 3531038 [TBL] [Abstract][Full Text] [Related]
59. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension. Germino FW Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484 [TBL] [Abstract][Full Text] [Related]